- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments -
- Dermata plans to launch its first OTC product, a once weekly acne kit with its Spongilla technology, in the middle of 2026 -
Read More
With 6-figure expectations this one of one 2009 Topps Unique Tom Brady card featuring a game-worn NFL Equipment patch and autograph is now live at Fanatics Collect's Premier Auction that ends Thursday, November 20, 2025 at 9:30 PM Eastern Time (EST).
Read MoreCompany to offer the first clinically validated dietary management of sarcopenia, now available for GLP-1 muscle loss, positioning Wellgistics to help 6,500+ independent pharmacy network (‘Pharmacy Network') and telehealth partners mitigate patient muscle loss in the GLP-1 drug market, estimated to grow to $150 billion by 2030
Company to offer first SARS-CoV-2 related natural antiviral combo for Long COVID with addition of 3CL protease inhibitor supplement Tollovid® to Galectovid 1 & 3 inhibitor Medical Food Galectovid® distribution agreement to Pharmacy Network & physicians
Quarterly Results Reflect First Full Quarter Including Wattbike (Acquisition Closed July 1)
Company Reports Record Quarterly Revenue of $4.8 Million; Net Loss and Loss per Diluted Share of $5.2 Million and $3.11; Quarterly Adjusted EBITDA Loss of $2.9 million, Due to Low Inventory Availability
Sportstech Acquisition Expected to Close in 2025 Based on Key Closing Milestone Achievements
Reiterates 2025 Pro Forma Revenue Guidance of more than $80 million and Fourth Quarter Profitability Guidance
Read MoreDigital olfactory commercialization accelerates toward 2026 scale-up, as industrial partnerships expand to six and the IP moat strengthens.
World's first patented commercial AI Nose device launched, advancing SmellTech-as-a-Service adoption.
Read MoreNet income from continuing operations of $5.9 million in Q3 2025
Gross margin increased 20.0% sequentially to 49.4%
Balance sheet at September 30, 2025, strongest in the Company's history with $81.5 million in DAT assets and cash, no debt and shareholders' equity of $78.7 million
Management expects continued positive momentum in Q4 2025
Read MoreTotal net revenue of $13.9 million
Net income of $2.0 million, or $0.21 net income per share basic
Adjusted EBITDA1 of $(0.6) million, which includes EXXUA launch investments
$32.6 million cash balance at September 30, 2025
Company remains on track to launch EXXUA™ (gepirone) extended-release tablets ("EXXUA") in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market
Company to host conference call and webcast today, November 13, 2025, at 4:30 p.m. Eastern time
Read More
Highlights for the Quarter ended September 30, 2025:
Management and advisory fee revenue of $17.8 million for the quarter ended September 30, 2025, a 36% increase from the third quarter of 2024
Management and advisory fee revenue of $55.5 million for the nine months ended September 30, 2025, a 49% increase from the nine months ended September 30, 2024.
Net income attributable to Horizon Kinetics Holding Corporation of $7.2 million, or $0.39 per common share for the three months ended September 30, 2025
Operating income for the third quarter of 2025 was $2.9 million, an increase of $3.9 million from a $0.9 million loss during the third quarter of 2024
Assets under management ("AUM") of $10.4 billion as of September 30, 2025, an increase of 5.2% from December 31, 2024 and 25% from September 30, 2024
Board of Directors declared a $0.106 per share dividend
MeaDea by Theo, presented under the divine creative umbrella of TheaMou (Θεά Μου - "My Goddess") debuts its newest collection at Athens Fashion Week on November 14th, 2025, titled: "Inspired by the Ancient Olympics" - The True Flame & The Origin of Light."
MeaDea by Theo Launches New Line at Athens Fashion Week Under TheaMou "My Goddess" Brand.
Read More
Advanced modeling powered by artificial intelligence (AI) indicates that Montauban may be more than a reclamation or redevelopment story - it may be emerging as the nucleus of a potentially much larger gold, silver, and base metal district.
Read MoreCrofelemer can potentially extend and save lives of microvillus inclusion disease patients, reducing the volume of the total parenteral support (PS) necessary for them to survive
Groundbreaking PS reduction of up to 37% is unprecedented; No approved treatments exist for MVID
Read More